Any feedback?
Information on EC 3.4.21.26 - prolyl oligopeptidase
for references in articles please use BRENDA:EC3.4.21.26Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
3.4.21.26 prolyl oligopeptidaseSpecify your search results
Word Map
- 3.4.21.26
-
dipeptidyl
-
stroma
-
cancer-associated
- aminopeptidase
- neuropeptides
- endopeptidases
- neurotensin
-
proline-containing
-
fapis
-
biodistribution
-
myofibroblasts
- flavobacterium
- celiac
-
beta-propeller
- bradykinin
- trh
- dppiv
- meningosepticum
-
3.4.14.5
-
18f-fdg
-
theranostic
-
exopeptidase
-
pyroglutamyl
- phosphoramidon
- amanita
- amnesia
-
carcinoma-associated
-
peptidase-iv
- pharmacology
-
ac-sdkp
-
seven-bladed
-
gluten-free
-
suvmean
- gliadin
-
n-acetyl-seryl-aspartyl-lysyl-proline
-
bispecific
-
acylpeptide
- medicine
- nutrition
- food industry
- drug development
The expected taxonomic range for this enzyme is: Bacteria, Archaea, Eukaryota
Synonyms
prolyl oligopeptidase, fibroblast activation protein, proline endopeptidase, post-proline cleaving enzyme, prolylendopeptidase, proline-specific endopeptidase, post-proline endopeptidase, glutenase, prolyl endoprotease, appep, 
more
top
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
endoprolylpeptidase
-
-
-
-
peptidase, postproline endo-
-
-
-
-
post-proline cleaving enzyme
-
-
-
-
post-proline endopeptidase
-
-
-
-
postproline endopeptidase
-
-
-
-
postproline-cleaving enzyme
-
-
-
-
proline endopeptidase
-
-
-
-
proline-specific endopeptidase
-
-
-
-
prolyl endopeptidase
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
72162-84-6
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acromegaly
Fibroblast activation protein is a GH target: A prospective study of patients with acromegaly before and after treatment.
Acute Coronary Syndrome
Circulating concentrations of fibroblast activation protein ? in apparently healthy individuals and patients with acute coronary syndrome as assessed by sandwich ELISA.
Acute Lung Injury
Effects of a natural prolyl oligopeptidase inhibitor, rosmarinic acid, on lipopolysaccharide-induced acute lung injury in mice.
Acute Lung Injury
The protective role of prolyl oligopeptidase (POP) inhibition in acute lung injury induced by intestinal ischemia-reperfusion.
Adenocarcinoma
Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma.
Adenocarcinoma
Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance.
Adenocarcinoma
Fibroblast activation protein and its prognostic significance in correlation with vascular endothelial growth factor in pancreatic adenocarcinoma.
Adenocarcinoma
Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma.
Adenocarcinoma
Fibroblast activation protein augments progression and metastasis of pancreatic ductal adenocarcinoma.
Adenocarcinoma
Noncontrast Magnetic Resonance Radiomics and Multilayer Perceptron Network Classifier: An approach for Predicting Fibroblast Activation Protein Expression in Patients With Pancreatic Ductal Adenocarcinoma.
Alzheimer Disease
Brain prolyl oligopeptidase activity is associated with neuronal damage rather than beta-amyloid accumulation.
Alzheimer Disease
Cholinesterase and Prolyl Oligopeptidase Inhibitory Activities of Alkaloids from Argemone platyceras (Papaveraceae).
Alzheimer Disease
Comparison of proline endopeptidase activity in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease.
Alzheimer Disease
In silico methods to identify meat-derived prolyl endopeptidase inhibitors.
Alzheimer Disease
Prolyl oligopeptidase colocalizes with ?-synuclein, ?-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson's and Alzheimer's diseases.
Alzheimer Disease
Quantitative structure-activity relationship of prolyl oligopeptidase inhibitory peptides derived from beta-casein using simple amino acid descriptors.
Alzheimer Disease
S 17092-1, a highly potent, specific and cell permeant inhibitor of human proline endopeptidase.
Amnesia
Unclosed beta-propellers display stable structures: implications for substrate access to the active site of prolyl oligopeptidase.
Amnesia
[Changes in proline-specific peptidase activity in experimental model of retrograde amnesia]
Arthritis
Circulating concentrations of fibroblast activation protein ? in apparently healthy individuals and patients with acute coronary syndrome as assessed by sandwich ELISA.
Arthritis
Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata.
Arthritis
Selective Homogeneous Assay for Circulating Endopeptidase Fibroblast Activation Protein (FAP).
Arthritis
Stromal cell markers are differentially expressed in the synovial tissue of patients with early arthritis.
Arthritis, Experimental
Imaging fibroblast activation protein to monitor therapeutic effects of neutralizing interleukin-22 in collagen-induced arthritis.
Arthritis, Rheumatoid
Circulating fibroblast activation protein and dipeptidyl peptidase 4 in rheumatoid arthritis and systemic sclerosis.
Arthritis, Rheumatoid
Inhibition of fibroblast activation protein and dipeptidyl peptidase IV increases cartilage invasion by rheumatoid arthritis synovial fibroblasts.
Arthritis, Rheumatoid
Targeting of fibroblast activation protein in rheumatoid arthritis patients: imaging and ex vivo photodynamic therapy.
Atherosclerosis
The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis.
Brain Diseases
Mechanism of Action of Prolyl Oligopeptidase (PREP) in Degenerative Brain Diseases: Has Peptidase Activity Only a Modulatory Role on the Interactions of PREP with Proteins?
Brain Ischemia
ZTTA, a postproline cleaving enzyme inhibitor, improves cerebral ischemia-induced deficits in a three-panel runway task in rats.
Breast Neoplasms
A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice.
Breast Neoplasms
Anti-tumor effects of DNA vaccine targeting human fibroblast activation protein ? by producing specific immune responses and altering tumor microenvironment in the 4T1 murine breast cancer model.
Breast Neoplasms
Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models.
Breast Neoplasms
Cyclophosphamide enhances anti-tumor effects of a fibroblast activation protein ?-based DNA vaccine in tumor-bearing mice with murine breast carcinoma.
Breast Neoplasms
Expression and targeting of human fibroblast activation protein in a human skin/severe combined immunodeficient mouse breast cancer xenograft model.
Breast Neoplasms
FAP Delineates Heterogeneous and Functionally Divergent Stromal Cells in Immune-Excluded Breast Tumors.
Breast Neoplasms
Fibroblast activation protein expression by stromal cells and tumor-associated macrophages in human breast cancer.
Breast Neoplasms
Immunization of stromal cell targeting fibroblast activation protein providing immunotherapy to breast cancer mouse model.
Breast Neoplasms
Improvement of anti-tumor immunity of fibroblast activation protein ? based vaccines by combination with cyclophosphamide in a murine model of breast cancer.
Breast Neoplasms
The prolyl oligopeptidase inhibitor SUAM-14746 attenuates the proliferation of human breast cancer cell lines in vitro.
Breast Neoplasms
Tumor elastography and its association with cell-free tumor DNA in the plasma of breast tumor patients: a pilot study.
Carcinogenesis
Expression of the Peptidase "Fibroblast Activation Protein" on Decidual Stromal Cells Facilitating Tissue Remodeling.
Carcinogenesis
Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity.
Carcinoma
Downregulation of FAP suppresses cell proliferation and metastasis through PTEN/PI3K/AKT and Ras-ERK signaling in oral squamous cell carcinoma.
Carcinoma
Enhancement of fibroblast activation protein ?-based vaccines and adenovirus boost immunity by cyclophosphamide through inhibiting IL-10 expression in 4T1 tumor bearing mice.
Carcinoma
Evaluation of the circulating level of fibroblast activation protein ? for diagnosis of esophageal squamous cell carcinoma.
Carcinoma
Fibroblast Activation Protein (FAP) Overexpression Induces Epithelial-Mesenchymal Transition (EMT) in Oral Squamous Cell Carcinoma by Down-Regulating Dipeptidyl Peptidase 9 (DPP9).
Carcinoma
Fibroblast activation protein and its prognostic significance in correlation with vascular endothelial growth factor in pancreatic adenocarcinoma.
Carcinoma
Fibroblast activation protein predicts prognosis in clear cell renal cell carcinoma.
Carcinoma
Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas.
Carcinoma
Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens.
Carcinoma
Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase.
Carcinoma
Integral membrane protease fibroblast activation protein sensitizes fibrosarcoma to chemotherapy and alters cell death mechanisms.
Carcinoma
Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy.
Carcinoma
Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer.
Carcinoma
Photodynamic molecular beacon triggered by fibroblast activation protein on cancer-associated fibroblasts for diagnosis and treatment of epithelial cancers.
Carcinoma
Photoimmunotherapy for cancer-associated fibroblasts targeting fibroblast activation protein in human esophageal squamous cell carcinoma.
Carcinoma
Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients.
Carcinoma
Species-crossreactive scFv against the tumor stroma marker "fibroblast activation protein" selected by phage display from an immunized FAP-/- knock-out mouse.
Carcinoma
Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity - initial experience and comparison to [18F]FDG PET/CT and MRI.
Carcinoma
The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder.
Carcinoma
The Expression of FAP in Hepatocellular Carcinoma Cells is Induced by Hypoxia and Correlates with Poor Clinical Outcomes.
Carcinoma
The Expression of Fibroblast Activation Protein in Clear Cell Renal Cell Carcinomas Is Associated with Synchronous Lymph Node Metastases.
Carcinoma
Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells.
Carcinoma
Whole Exome Sequencing Reveals a Novel Damaging Mutation in Human Fibroblast Activation Protein in a Family with Esophageal Squamous Cell Carcinoma.
Carcinoma, Hepatocellular
Increased expression of CCN2, epithelial membrane antigen, and fibroblast activation protein in hepatocellular carcinoma with fibrous stroma showing aggressive behavior.
Carcinoma, Hepatocellular
Neuropeptide Y is a physiological substrate of fibroblast activation protein: Enzyme kinetics in blood plasma and expression of Y2R and Y5R in human liver cirrhosis and hepatocellular carcinoma.
Carcinoma, Hepatocellular
[Expression of fibroblast activation protein in HBV related hepatocellular carcinoma].
Carcinoma, Non-Small-Cell Lung
Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer.
Carcinoma, Ovarian Epithelial
Fibroblast activation protein regulates tumor-associated fibroblasts and epithelial ovarian cancer cells.
Carcinoma, Ovarian Epithelial
Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer.
Carcinoma, Renal Cell
Fibroblast activation protein predicts prognosis in clear cell renal cell carcinoma.
Carcinoma, Renal Cell
The Expression of Fibroblast Activation Protein in Clear Cell Renal Cell Carcinomas Is Associated with Synchronous Lymph Node Metastases.
Carcinoma, Squamous Cell
Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity - initial experience and comparison to [18F]FDG PET/CT and MRI.
Cardiotoxicity
Fibroblast Activation Protein ? Activated Tripeptide Bufadienolide Antitumor Prodrug with Reduced Cardiotoxicity.
Cardiovascular Diseases
Relationship Between Cardiac Fibroblast Activation Protein Activity by Positron Emission Tomography and Cardiovascular Disease.
Celiac Disease
Generation of food-grade recombinant Lactobacillus casei delivering Myxococcus xanthus prolyl endopeptidase.
Celiac Disease
Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease.
Celiac Disease
The Glutenase ALV003 Attenuates Gluten-Induced Mucosal Injury in Patients with Celiac Disease.
Chagas Disease
Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine.
Cholangiocarcinoma
Expression of fibroblast activation protein and the clinicopathological relevance in distal cholangiocarcinoma.
Colonic Neoplasms
Clinical implications of fibroblast activation protein in patients with colon cancer.
Colonic Neoplasms
High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis.
Colonic Neoplasms
Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model.
Colonic Neoplasms
Protumorigenic effects of Snail-expression fibroblasts on colon cancer cells.
Colonic Neoplasms
Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer.
Colorectal Neoplasms
Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts.
Colorectal Neoplasms
Colorectal cancer cells activate adjacent fibroblasts resulting in FGF1/FGFR3 signaling and increased invasion.
Colorectal Neoplasms
Comparisons of cancer-associated fibroblasts in the intratumoral stroma and invasive front in colorectal cancer.
Colorectal Neoplasms
Distribution of prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal tumors.
Colorectal Neoplasms
High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis.
Colorectal Neoplasms
Phase II Trial of Single Agent Val-boroPro (Talabostat) Inhibiting Fibroblast Activation Protein in Patients with Metastatic Colorectal Cancer.
Colorectal Neoplasms
Predictive values of FAP and HGF for tumor angiogenesis and metastasis in colorectal cancer.
Colorectal Neoplasms
[Expression and clinical significance of fibroblast activation protein in colorectal carcinoma tissue].
Corneal Neovascularization
Expression of MMP, HPSE, and FAP in stroma promoted corneal neovascularization induced by different etiological factors.
Corneal Neovascularization
[Relationship between corneal neovascularization and various relevant biological factors in surrounding cornea stroma of rats]
Coronary Disease
Circulating fibroblast activation protein activity and antigen levels correlate strongly when measured in liver disease and coronary heart disease.
Crohn Disease
Inhibition of Fibroblast Activation Protein Restores a Balanced Extracellular Matrix and Reduces Fibrosis in Crohn's Disease Strictures Ex Vivo.
Dementia
Comparison of proline endopeptidase activity in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease.
Dementia
Deficiency of prolyl oligopeptidase in mice disturbs synaptic plasticity and reduces anxiety-like behaviour, body weight, and brain volume.
Diabetes Mellitus, Type 2
Crystal structures of human dipeptidyl peptidase IV in its apo and diprotin B-complexed forms.
Diabetes Mellitus, Type 2
FGF21 is an insulin-dependent postprandial hormone in adult humans.
Diabetes Mellitus, Type 2
Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity.
Epilepsy
Spatiotemporal expression and inhibition of prolyl oligopeptidase contradict its involvement in key pathologic mechanisms of kainic acid-induced temporal lobe epilepsy in rats.
Epilepsy, Temporal Lobe
Spatiotemporal expression and inhibition of prolyl oligopeptidase contradict its involvement in key pathologic mechanisms of kainic acid-induced temporal lobe epilepsy in rats.
Esophageal Diseases
Evaluation of the circulating level of fibroblast activation protein ? for diagnosis of esophageal squamous cell carcinoma.
Esophageal Neoplasms
Fibroblast activation protein targeted near infrared photoimmunotherapy (NIR PIT) overcomes therapeutic resistance in human esophageal cancer.
Esophageal Neoplasms
Impact of Primary Staging with Fibroblast Activation Protein Specific Enzyme Inhibitor (FAPI)-PET/CT on Radio-Oncologic Treatment Planning of Patients with Esophageal Cancer.
Esophageal Squamous Cell Carcinoma
Evaluation of the circulating level of fibroblast activation protein ? for diagnosis of esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Photoimmunotherapy for cancer-associated fibroblasts targeting fibroblast activation protein in human esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Whole Exome Sequencing Reveals a Novel Damaging Mutation in Human Fibroblast Activation Protein in a Family with Esophageal Squamous Cell Carcinoma.
Fatty Liver
Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity.
Fibrosarcoma
Dataset on FAP-induced emergence of spontaneous metastases and on the preparation of activatable FAP-targeting immunoliposomes to detect the metastases.
Fibrosarcoma
Fibroblast activation protein increases metastatic potential of fibrosarcoma line HT1080 through upregulation of integrin-mediated signaling pathways.
Fibrosarcoma
Integral membrane protease fibroblast activation protein sensitizes fibrosarcoma to chemotherapy and alters cell death mechanisms.
Fibrosarcoma
Potential of activatable FAP-targeting immunoliposomes in intraoperative imaging of spontaneous metastases.
Genetic Diseases, Inborn
Molecular dynamics, crystallography and mutagenesis studies on the substrate gating mechanism of prolyl oligopeptidase.
Glioblastoma
Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy.
Glioblastoma
FAP-specific PET signaling shows a moderately positive correlation with relative CBV and no correlation with ADC in 13 IDH wildtype glioblastomas.
Glioblastoma
Fibroblast Activation Protein (FAP) specific PET for advanced target volume delineation in glioblastoma.
Glioblastoma
Fibroblast Activation Protein Expressing Mesenchymal Cells Promote Glioblastoma Angiogenesis.
Glioblastoma
Heterogeneity of molecular forms of dipeptidyl peptidase-IV and fibroblast activation protein in human glioblastomas.
Glioblastoma
Regulation of Fibroblast Activation Protein by Transforming Growth Factor Beta-1 in Glioblastoma Microenvironment.
Glioma
Dipeptidyl peptidase-IV inhibits glioma cell growth independent of its enzymatic activity.
Glioma
Rational Design, Pharmacomodulation, and Synthesis of [68Ga]Ga-Alb-FAPtp-01, a Selective Tumor-Associated Fibroblast Activation Protein Tracer for PET Imaging of Glioma.
Granuloma
An improved noninfectious murine skin model of organized granulomatous inflammation.
Head and Neck Neoplasms
Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers.
Hematologic Neoplasms
Detecting fibroblast activation proteins in lymphoma using 68Ga-FAPI PET/CT.
Hepatitis C
Intrahepatic expression of collagen and fibroblast activation protein (FAP) in hepatitis C virus infection.
Hepatitis C
Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection.
Huntington Disease
Comparison of proline endopeptidase activity in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease.
Huntington Disease
Decreased proline endopeptidase activity in the basal ganglia in Huntington's disease.
Huntington Disease
Prolyl oligopeptidase inhibition reduces PolyQ aggregation and improves cell viability in cellular model of Huntington's disease.
Hypersensitivity
Significant accumulations of cathepsin B and prolylendopeptidase in inflammatory focus of delayed-type hypersensitivity induced by Mycobacterium tuberculosis in mice.
Hypertension
Distribution of prolyl oligopeptidase in human peripheral tissues and body fluids.
Hypertension
Increased angiotensin II-induced hypertension and inflammatory cytokines in mice lacking angiotensin-converting enzyme N domain activity.
Idiopathic Pulmonary Fibrosis
Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis.
Idiopathic Pulmonary Fibrosis
Loss of cells expressing fibroblast activation protein has variable effects in models of TGF-? and chronic bleomycin-induced fibrosis.
Immunoglobulin G4-Related Disease
Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging.
Immunoglobulin G4-Related Disease
Fibroblast activation protein targeted PET/CT with 68Ga-FAPI for imaging IgG4-related disease: comparison to 18F-FDG PET/CT.
Infections
Identification of novel Trypanosoma cruzi prolyl oligopeptidase inhibitors by structure-based virtual screening.
Infections
Prolyl Oligopeptidase From Leishmania infantum: Biochemical Characterization and Involvement in Macrophage Infection.
Insulinoma
Evidence for pyroglutamyl peptidase I and prolyl endopeptidase activities in the rat insulinoma cell line RINm 5F: lack of relationship with TRH metabolism.
Ischemic Stroke
Acute Ischemic Stroke Severity, Progression, and Outcome Relate to Changes in Dipeptidyl Peptidase IV and Fibroblast Activation Protein Activity.
Ischemic Stroke
Incorporation of ?2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients.
Joint Diseases
Increased uptake of 68Ga-DOTA-FAPI-04 in bones and joints: metastases and beyond.
Kidney Neoplasms
Fibroblast activation protein predicts prognosis in clear cell renal cell carcinoma.
Leukemia
Intracellular activation and deactivation of tasidotin, an analog of dolastatin 15: correlation with cytotoxicity.
Leukemia, Myeloid, Acute
Expression and role of fibroblast activation protein ? in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Prolyl oligopeptidase inhibitor suppresses the upregulation of ACSDKP in patients with acute myeloid leukemia.
Lewy Body Disease
Comparison of proline endopeptidase activity in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease.
Liver Cirrhosis
Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity.
Liver Cirrhosis
Neuropeptide Y is a physiological substrate of fibroblast activation protein: Enzyme kinetics in blood plasma and expression of Y2R and Y5R in human liver cirrhosis and hepatocellular carcinoma.
Liver Diseases
Circulating fibroblast activation protein activity and antigen levels correlate strongly when measured in liver disease and coronary heart disease.
Liver Diseases
Extraenzymatic functions of the dipeptidyl peptidase IV-related proteins DP8 and DP9 in cell adhesion, migration and apoptosis.
Liver Diseases
Immunoglobulin G4-Related Sclerosing Cholangitis Revealed by 68Ga-FAPI PET/MR.
Liver Diseases
Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity.
Liver Failure
The expression levels of prolyl oligopeptidase responds not only to neuroinflammation but also to systemic inflammation upon liver failure in rat models and cirrhotic patients.
Liver Neoplasms
Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT.
Lung Diseases, Interstitial
Fibroblast Activation Protein specific PET/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study.
Lung Neoplasms
Epidural adipose tissue-derived mesenchymal stem cell activation induced by lung cancer cells promotes malignancy and EMT of lung cancer.
Lung Neoplasms
Fibroblast Activation Protein specific PET/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study.
Lung Neoplasms
Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer.
Lymphatic Metastasis
Fibroblast activation protein-positive fibroblasts promote tumor progression through secretion of CCL2 and interleukin-6 in esophageal squamous cell carcinoma.
Lymphatic Metastasis
The Expression of Fibroblast Activation Protein in Clear Cell Renal Cell Carcinomas Is Associated with Synchronous Lymph Node Metastases.
Malnutrition
Undernutrition during suckling does not change the specific or total activity of hypothalamic proline endopeptidase in adult rats.
Melanoma
Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression.
Melanoma
Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma.
Melanoma, Experimental
Vaccine-induced CD8 T cells are redirected with peptide-MHC class I-IgG antibody fusion proteins to eliminate tumor cells in vivo.
Memory Disorders
Electrostatic effects and binding determinants in the catalysis of prolyl oligopeptidase. Site specific mutagenesis at the oxyanion binding site.
Memory Disorders
Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research.
Memory Disorders
Substrate- and pH-dependent contribution of oxyanion binding site to the catalysis of prolyl oligopeptidase, a paradigm of the serine oligopeptidase family.
Memory Disorders
Substrate-dependent competency of the catalytic triad of prolyl oligopeptidase.
Memory Disorders
The noncatalytic beta-propeller domain of prolyl oligopeptidase enhances the catalytic capability of the peptidase domain.
Mesothelioma
Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial.
Mesothelioma
Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).
Mesothelioma, Malignant
Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).
Monoclonal Gammopathy of Undetermined Significance
Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma.
Mouth Neoplasms
Genomewide mRNA profiling of esophageal squamous cell carcinoma for identification of cancer biomarkers.
Mouth Neoplasms
Human telomerase reverse transcriptase (hTERT) promotes cancer invasion by modulating cathepsin D via early growth response (EGR)-1.
Multiple Myeloma
Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through ?-catenin signaling pathway.
Multiple Myeloma
Multiple Myeloma Bone Marrow Mesenchymal Stromal Cells Inhibit CD8+ T Cell Function in a Process that May Implicate Fibroblast Activation Protein ?.
Multiple Sclerosis
Alteration of prolyl oligopeptidase and activated ?-2-macroglobulin in multiple sclerosis subtypes and in the clinically isolated syndrome.
Multiple Sclerosis
The expression levels of prolyl oligopeptidase responds not only to neuroinflammation but also to systemic inflammation upon liver failure in rat models and cirrhotic patients.
Multiple Sclerosis, Relapsing-Remitting
Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis.
Multiple System Atrophy
Prolyl oligopeptidase inhibition reduces alpha-synuclein aggregation in a cellular model of multiple system atrophy.
Myocardial Infarction
Imaging of cardiac fibroblast activation in a patient after acute myocardial infarction using 68Ga-FAPI-04.
Myocardial Infarction
Molecular imaging of fibroblast activation protein after myocardial infarction using the novel radiotracer [68Ga]MHLL1.
Myocardial Infarction
Molecular imaging of fibroblast activity after myocardial infarction using a 68Ga-labelled fibroblast activation protein inhibitor FAPI-04.
Nasopharyngeal Carcinoma
Clinical utility of [68Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma.
Neoplasm Metastasis
68Ga-FAPI-04 vs. 18F-FDG in a longitudinal preclinical PET imaging of metastatic breast cancer.
Neoplasm Metastasis
Dataset on FAP-induced emergence of spontaneous metastases and on the preparation of activatable FAP-targeting immunoliposomes to detect the metastases.
Neoplasm Metastasis
Fibroblast activation protein augments progression and metastasis of pancreatic ductal adenocarcinoma.
Neoplasm Metastasis
Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours.
Neoplasm Metastasis
Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis.
Neoplasm Metastasis
Fibroblast activation protein-positive fibroblasts promote tumor progression through secretion of CCL2 and interleukin-6 in esophageal squamous cell carcinoma.
Neoplasm Metastasis
Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens.
Neoplasm Metastasis
Immunization of stromal cell targeting fibroblast activation protein providing immunotherapy to breast cancer mouse model.
Neoplasm Metastasis
Potential of activatable FAP-targeting immunoliposomes in intraoperative imaging of spontaneous metastases.
Neoplasm Metastasis
Predictive values of FAP and HGF for tumor angiogenesis and metastasis in colorectal cancer.
Neoplasm Metastasis
Roles of Fibroblast Activation Protein and Hepatocyte Growth Factor Expressions in Angiogenesis and Metastasis of Gastric Cancer.
Neoplasm Metastasis
The Expression of Fibroblast Activation Protein in Clear Cell Renal Cell Carcinomas Is Associated with Synchronous Lymph Node Metastases.
Neoplasms
68Ga-FAPI-04 PET/MR is helpful in differential diagnosis of pancreatitis from pancreatic malignancy compared to 18F-FDG PET/CT: a case report.
Neoplasms
68Ga-FAPI-04 vs. 18F-FDG in a longitudinal preclinical PET imaging of metastatic breast cancer.
Neoplasms
68Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas - Imaging analysis and histological validation.
Neoplasms
A case of nonfunctioning pancreatic endocrine tumor with atypical imaging findings due to prominent fibrosis of the tumor stroma.
Neoplasms
A multi-antigen vaccine in combination with an immunotoxin targeting tumor-associated fibroblast for treating murine melanoma.
Neoplasms
A new tumor vaccine: FAP?-MT elicits effective antitumor response by targeting Indolamine2, 3-dioxygenase in antigen presenting cells.
Neoplasms
A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy.
Neoplasms
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
Neoplasms
A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice.
Neoplasms
A rare variant in human fibroblast activation protein associated with ER stress, loss of enzymatic function and loss of cell surface localisation.
Neoplasms
A specific, transmembrane interface regulates fibroblast activation protein (FAP) homodimerization, trafficking and exopeptidase activity.
Neoplasms
A synthetic urinary probe-coated nanoparticles sensitive to fibroblast activation protein ? for solid tumor diagnosis.
Neoplasms
A vaccine that co-targets tumor cells and cancer associated fibroblasts results in enhanced antitumor activity by inducing antigen spreading.
Neoplasms
A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts.
Neoplasms
Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth.
Neoplasms
Activatable bispecific liposomes bearing fibroblast activation protein directed single chain fragment/Trastuzumab deliver encapsulated cargo into the nuclei of tumor cells and the tumor microenvironment simultaneously.
Neoplasms
Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression.
Neoplasms
Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization.
Neoplasms
Ala657 and conserved active site residues promote fibroblast activation protein endopeptidase activity via distinct mechanisms of transition state stabilization.
Neoplasms
Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice.
Neoplasms
An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site.
Neoplasms
Anti-tumor effects of DNA vaccine targeting human fibroblast activation protein ? by producing specific immune responses and altering tumor microenvironment in the 4T1 murine breast cancer model.
Neoplasms
Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts.
Neoplasms
Author Correction: A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts.
Neoplasms
Bispecific single-chain diabody-immunoliposomes targeting endoglin (CD105) and fibroblast activation protein (FAP) simultaneously.
Neoplasms
Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma.
Neoplasms
Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model.
Neoplasms
Cancer-associated fibroblasts downregulate type I interferon receptor to stimulate intratumoral stromagenesis.
Neoplasms
Cancer-associated fibroblasts secrete hypoxia-induced serglycin to promote head and neck squamous cell carcinoma tumor cell growth in vitro and in vivo by activating the Wnt/?-catenin pathway.
Neoplasms
Carboxypeptidase in prolyl oligopeptidase family: Unique enzyme activation and substrate-screening mechanisms.
Neoplasms
CD117 expression in fibroblasts-like stromal cells indicates unfavorable clinical outcomes in ovarian carcinoma patients.
Neoplasms
CD40 Agonist Targeted to Fibroblast Activation Protein ? Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors.
Neoplasms
Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma.
Neoplasms
Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin.
Neoplasms
Circulating concentrations of fibroblast activation protein ? in apparently healthy individuals and patients with acute coronary syndrome as assessed by sandwich ELISA.
Neoplasms
Clinical implications of fibroblast activation protein in patients with colon cancer.
Neoplasms
Clinical translational evaluation of Al18F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging.
Neoplasms
Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8.
Neoplasms
Comparisons of cancer-associated fibroblasts in the intratumoral stroma and invasive front in colorectal cancer.
Neoplasms
Construction of a bispecific single chain antibody for recruitment of cytotoxic T cells to the tumour stroma associated antigen fibroblast activation protein.
Neoplasms
Corrigendum: A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts.
Neoplasms
COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset.
Neoplasms
Curcumin combined with FAP?c vaccine elicits effective antitumor response by targeting indolamine-2,3-dioxygenase and inhibiting EMT induced by TNF-? in melanoma.
Neoplasms
Cyclophosphamide enhances anti-tumor effects of a fibroblast activation protein ?-based DNA vaccine in tumor-bearing mice with murine breast carcinoma.
Neoplasms
Dataset on FAP-induced emergence of spontaneous metastases and on the preparation of activatable FAP-targeting immunoliposomes to detect the metastases.
Neoplasms
Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors.
Neoplasms
Design and validation of fibroblast activation protein alpha targeted imaging and therapeutic agents.
Neoplasms
Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21.
Neoplasms
Distribution of prolyl oligopeptidase in human peripheral tissues and body fluids.
Neoplasms
Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy.
Neoplasms
Enhancement of fibroblast activation protein ?-based vaccines and adenovirus boost immunity by cyclophosphamide through inhibiting IL-10 expression in 4T1 tumor bearing mice.
Neoplasms
Evaluation of the circulating level of fibroblast activation protein ? for diagnosis of esophageal squamous cell carcinoma.
Neoplasms
Expression and targeting of human fibroblast activation protein in a human skin/severe combined immunodeficient mouse breast cancer xenograft model.
Neoplasms
Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy.
Neoplasms
Expression of fibroblast activation protein and the clinicopathological relevance in distal cholangiocarcinoma.
Neoplasms
Expression of the FAP gene in non-fibroblast human cell lines. Development of cancer-associated fibroblast models.
Neoplasms
Expression profiling of dipeptidyl peptidase 8 and 9 in breast and ovarian carcinoma cell lines.
Neoplasms
FAPI-PET/CT: biodistribution and preliminary dosimetry estimate of two DOTA-containing FAP-targeting agents in patients with various cancers.
Neoplasms
Feasibility and Therapeutic Potential of 177Lu-Fibroblast Activation Protein Inhibitor-46 for Patients With Relapsed or Refractory Cancers: A Preliminary Study.
Neoplasms
Feasibility, Biodistribution and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy (PTRT) of Diverse Adenocarcinomas using 177Lu-FAP-2286: First-in-Human Results.
Neoplasms
Fibroblast Activation Protein (FAP) Overexpression Induces Epithelial-Mesenchymal Transition (EMT) in Oral Squamous Cell Carcinoma by Down-Regulating Dipeptidyl Peptidase 9 (DPP9).
Neoplasms
Fibroblast Activation Protein (FAP) specific PET for advanced target volume delineation in glioblastoma.
Neoplasms
Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma.
Neoplasms
Fibroblast Activation Protein ?-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity.
Neoplasms
Fibroblast activation protein alpha is expressed by transformed and stromal cells and is associated with mesenchymal features in glioblastoma.
Neoplasms
Fibroblast activation protein and its prognostic significance in correlation with vascular endothelial growth factor in pancreatic adenocarcinoma.
Neoplasms
Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma.
Neoplasms
Fibroblast Activation Protein Expressing Mesenchymal Cells Promote Glioblastoma Angiogenesis.
Neoplasms
Fibroblast activation protein in osteosarcoma cells promotes angiogenesis via AKT and ERK signaling pathways.
Neoplasms
Fibroblast activation protein increases metastatic potential of fibrosarcoma line HT1080 through upregulation of integrin-mediated signaling pathways.
Neoplasms
Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours.
Neoplasms
Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes.
Neoplasms
Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata.
Neoplasms
Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis.
Neoplasms
Fibroblast activation protein predicts prognosis in clear cell renal cell carcinoma.
Neoplasms
Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through ?-catenin signaling pathway.
Neoplasms
Fibroblast activation protein regulates lesion burden and the fibro-inflammatory response in Apoe-deficient mice in a sexually dimorphic manner.
Neoplasms
Fibroblast activation protein restrains adipogenic differentiation and regulates matrix-mediated mTOR signaling.
Neoplasms
Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model.
Neoplasms
Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts.
Neoplasms
Fibroblast activation protein, a potential diagnostic and therapeutic target for cancer.
Neoplasms
Fibroblast activation protein-positive fibroblasts promote tumor progression through secretion of CCL2 and interleukin-6 in esophageal squamous cell carcinoma.
Neoplasms
Fibroblast activation protein: differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors.
Neoplasms
Fibroblast activation protein: purification, epitope mapping and induction by growth factors.
Neoplasms
Fusion of the tissue factor extracellular domain to a tumour stroma specific single-chain fragment variable antibody results in an antigen-specific coagulation-promoting molecule.
Neoplasms
Ga-68-FAPI as diagnostic tool in sarcoma: Data from the FAPI-PET prospective observational trial.
Neoplasms
Generation of human high-affinity antibodies specific for the fibroblast activation protein by guided selection.
Neoplasms
High Expression of FAP in Colorectal Cancer Is Associated With Angiogenesis and Immunoregulation Processes.
Neoplasms
Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours.
Neoplasms
Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas.
Neoplasms
Human telomerase reverse transcriptase (hTERT) promotes cancer invasion by modulating cathepsin D via early growth response (EGR)-1.
Neoplasms
Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens.
Neoplasms
IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
Neoplasms
Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules.
Neoplasms
Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia.
Neoplasms
Immunization of stromal cell targeting fibroblast activation protein providing immunotherapy to breast cancer mouse model.
Neoplasms
Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model.
Neoplasms
Impact of FAPI-PET/CT on Target Volume Definition in Radiation Therapy of Locally Recurrent Pancreatic Cancer.
Neoplasms
Improved cancer detection in Waldeyer's tonsillar ring by 68Ga-FAPI PET/CT imaging.
Neoplasms
Improvement of anti-tumor immunity of fibroblast activation protein ? based vaccines by combination with cyclophosphamide in a murine model of breast cancer.
Neoplasms
Increased angiotensin II-induced hypertension and inflammatory cytokines in mice lacking angiotensin-converting enzyme N domain activity.
Neoplasms
Increased expression of stemness markers and altered tumor stroma in hepatocellular carcinoma under TACE-induced hypoxia: A biopsy and resection matched study.
Neoplasms
Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
Neoplasms
Initial clinical experience with 90Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients.
Neoplasms
Laser Capture Microdissection of Epithelial Cancers Guided by Antibodies Against Fibroblast Activation Protein and Endosialin.
Neoplasms
MM-BMSCs induce naïve CD4+ T lymphocytes dysfunction through fibroblast activation protein ?.
Neoplasms
Molecular recognition of fibroblast activation protein for diagnostic and therapeutic applications.
Neoplasms
Mouse fibroblast activation protein: molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers.
Neoplasms
Nanoparticle formulation of mycophenolate mofetil achieves enhanced efficacy against hepatocellular carcinoma by targeting tumour-associated fibroblast.
Neoplasms
Neuropeptide Y is a physiological substrate of fibroblast activation protein: Enzyme kinetics in blood plasma and expression of Y2R and Y5R in human liver cirrhosis and hepatocellular carcinoma.
Neoplasms
One-pot and one-step automated radio-synthesis of [18F]AlF-FAPI-74 using a multi purpose synthesizer: a proof-of-concept experiment.
Neoplasms
Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy.
Neoplasms
Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents.
Neoplasms
Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer.
Neoplasms
Phase II Trial of Single Agent Val-boroPro (Talabostat) Inhibiting Fibroblast Activation Protein in Patients with Metastatic Colorectal Cancer.
Neoplasms
Photodynamic molecular beacon triggered by fibroblast activation protein on cancer-associated fibroblasts for diagnosis and treatment of epithelial cancers.
Neoplasms
Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients.
Neoplasms
Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics.
Neoplasms
Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model.
Neoplasms
PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism.
Neoplasms
Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs.
Neoplasms
Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies.
Neoplasms
Rapid fibroblast activation in mammalian cells induced by silicon nanowire arrays.
Neoplasms
Rapid Target Binding and Cargo Release of Activatable Liposomes Bearing HER2 and FAP Single-Chain Antibody Fragments Reveal Potentials for Image-Guided Delivery to Tumors.
Neoplasms
Rational Design, Pharmacomodulation, and Synthesis of [68Ga]Ga-Alb-FAPtp-01, a Selective Tumor-Associated Fibroblast Activation Protein Tracer for PET Imaging of Glioma.
Neoplasms
Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy.
Neoplasms
Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin.
Neoplasms
Regulation of Fibroblast Activation Protein by Transforming Growth Factor Beta-1 in Glioblastoma Microenvironment.
Neoplasms
Rhabdomyosarcoma Cells Produce Their Own Extracellular Matrix With Minimal Involvement of Cancer-Associated Fibroblasts: A Preliminary Study.
Neoplasms
Selective Activation of Anticancer Chemotherapy by Cancer-Associated Fibroblasts in the Tumor Microenvironment.
Neoplasms
Selective Homogeneous Assay for Circulating Endopeptidase Fibroblast Activation Protein (FAP).
Neoplasms
Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold.
Neoplasms
Short hairpin RNA targeting of fibroblast activation protein inhibits tumor growth and improves the tumor microenvironment in a mouse model.
Neoplasms
Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells.
Neoplasms
Species-crossreactive scFv against the tumor stroma marker "fibroblast activation protein" selected by phage display from an immunized FAP-/- knock-out mouse.
Neoplasms
Species-specific real-time RT-PCR analysis of expression of stromal cell genes in a tumor xenotransplantation model in mice.
Neoplasms
Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitro.
Neoplasms
State-of-the-art modalities in cardio-oncology: insight from a nuclear medicine approach.
Neoplasms
Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer.
Neoplasms
Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast.
Neoplasms
Structural revision of kynapcin-12 by total synthesis, and inhibitory activities against prolyl oligopeptidase and cancer cells.
Neoplasms
Structure-activity relationship and biochemical evaluation of novel fibroblast activation protein and prolyl endopeptidase inhibitors with ?-ketoamide warheads.
Neoplasms
Suppression of tumor growth in mice by rationally designed pseudopeptide inhibitors of fibroblast activation protein and prolyl oligopeptidase.
Neoplasms
Targeted lipid-coated nanoparticles: Delivery of tumor necrosis factor-functionalized particles to tumor cells.
Neoplasms
Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug.
Neoplasms
Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators.
Neoplasms
Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.
Neoplasms
Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice.
Neoplasms
Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18F-labeled FAP Inhibitor.
Neoplasms
Targeting inhibition of fibroblast activation protein-? and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments.
Neoplasms
Targeting of cancer?associated fibroblasts enhances the efficacy of cancer chemotherapy by regulating the tumor microenvironment.
Neoplasms
Targeting the Tumor Microenvironment with Fluorescence-Activatable Bispecific Endoglin/Fibroblast Activation Protein Targeting Liposomes.
Neoplasms
Targeting the tumor stroma as a novel treatment strategy for breast cancer: shifting from the neoplastic cell-centric to a stroma-centric paradigm.
Neoplasms
Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake.
Neoplasms
TGF-beta-induced fibroblast activation protein expression, fibroblast activation protein expression increases the proliferation, adhesion, and migration of HO-8910PM.
Neoplasms
The application of prostate specific membrane antigen in CART?cell therapy for treatment of prostate carcinoma (Review).
Neoplasms
The application of the fibroblast activation protein ?-targeted immunotherapy strategy.
Neoplasms
The development and validation of a combined kinetic fluorometric activity assay for fibroblast activation protein alpha and prolyl oligopeptidase in plasma.
Neoplasms
The effect of ALA-PDT on reversing the activation of cancer-associated fibroblasts in cutaneous squamous cell carcinoma.
Neoplasms
The fibroblast surface markers FAP, anti-fibroblast, and FSP are expressed by cells of epithelial origin and may be altered during epithelial-to-mesenchymal transition.
Neoplasms
The road to integrative cancer therapies: emergence of a tumor-associated fibroblast protease as a potential therapeutic target in cancer.
Neoplasms
The role of FAPI-PET/CT for patients with malignancies of the lower gastrointestinal tract - first clinical experience.
Neoplasms
Theranostics targeting fibroblast activation protein in the tumor stroma: 64Cu and 225Ac labelled FAPI-04 in pancreatic cancer xenograft mouse models.
Neoplasms
Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
Neoplasms
Tumor elastography and its association with cell-free tumor DNA in the plasma of breast tumor patients: a pilot study.
Neoplasms
Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts.
Neoplasms
Tumor-associated mesothelial cells are negative prognostic factors in gastric cancer and promote peritoneal dissemination of adherent gastric cancer cells by chemotaxis.
Neoplasms
Ultrasensitive Fluorescent Probes Reveal an Adverse Action of Dipeptide Peptidase IV and Fibroblast Activation Protein during Proliferation of Cancer Cells.
Neoplasms
Understanding fibroblast activation protein (FAP): Substrates, activities, expression and targeting for cancer therapy.
Neoplasms
Using Substrate Specificity of Antiplasmin-cleaving Enzyme for Fibroblast Activation Protein Inhibitor Design.
Neoplasms
UV radiation promotes melanoma dissemination mediated by the sequential reaction axis of cathepsins-TGF-?1-FAP-?.
Neoplasms
Vaccine-induced CD8 T cells are redirected with peptide-MHC class I-IgG antibody fusion proteins to eliminate tumor cells in vivo.
Nervous System Diseases
Brain Pharmacokinetics of Two Prolyl Oligopeptidase Inhibitors, JTP-4819 and KYP-2047, in the Rat.
Nervous System Diseases
Investigation of novel chemical scaffolds targeting prolyl oligopeptidase for neurological therapeutics.
Nervous System Diseases
Use of Umbrella Sampling to Calculate the Entrance/Exit Pathway for Z-Pro-Prolinal Inhibitor in Prolyl Oligopeptidase.
Neuroblastoma
A prolyl oligopeptidase inhibitor, Z-Pro-Prolinal, inhibits glyceraldehyde-3-phosphate dehydrogenase translocation and production of reactive oxygen species in CV1-P cells exposed to 6-hydroxydopamine.
Neuroblastoma
COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset.
Neuroblastoma
Inhibition of prolylendopeptidase does not affect gamma-secretase processing of amyloid precursor protein in a human neuroblastoma cell line.
Neuroblastoma
Prolyl oligopeptidase is a glyceraldehyde-3-phosphate dehydrogenase-binding protein that regulates genotoxic stress-induced cell death.
Neuroblastoma
Prolyl oligopeptidase participates in cell cycle progression in a human neuroblastoma cell line.
Neuroblastoma
Prolyl oligopeptidase participates in the cytosine arabinoside-induced nuclear translocation of glyceraldehyde 3-phosphate dehydrogenase in a human neuroblastoma cell line.
Neurodegenerative Diseases
Alteration of prolyl oligopeptidase and activated ?-2-macroglobulin in multiple sclerosis subtypes and in the clinically isolated syndrome.
Neurodegenerative Diseases
Effect of prolyl endopeptidase inhibition on arginine-vasopressin and thyrotrophin-releasing hormone catabolism in the rat brain.
Neurodegenerative Diseases
New tricks of prolyl oligopeptidase inhibitors - A common drug therapy for several neurodegenerative diseases.
Neurodegenerative Diseases
Prolyl oligopeptidase inhibition activates autophagy via protein phosphatase 2A.
Neurodegenerative Diseases
Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research.
Neurodegenerative Diseases
Purification, characterization and the use of recombinant prolyl oligopeptidase from Myxococcus xanthus for gluten hydrolysis.
Neurodegenerative Diseases
Spatiotemporal expression and inhibition of prolyl oligopeptidase contradict its involvement in key pathologic mechanisms of kainic acid-induced temporal lobe epilepsy in rats.
Neurodegenerative Diseases
Synthesis and biological evaluation of novel (123)I-labeled 4-(4-iodophenyl)butanoyl-L-prolyl-(2S)-pyrrolidines for imaging prolyl oligopeptidase in vivo.
Neurodegenerative Diseases
Targeted Covalent Inhibition of Prolyl Oligopeptidase (POP): Discovery of Sulfonylfluoride Peptidomimetics.
Neurodegenerative Diseases
The expression levels of prolyl oligopeptidase responds not only to neuroinflammation but also to systemic inflammation upon liver failure in rat models and cirrhotic patients.
Neurodegenerative Diseases
Triosephosphate isomerase deficiency: consequences of an inherited mutation at mRNA, protein and metabolic levels.
Neuroendocrine Tumors
Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours.
Neuroinflammatory Diseases
Deficiency of prolyl oligopeptidase in mice disturbs synaptic plasticity and reduces anxiety-like behaviour, body weight, and brain volume.
Neuroinflammatory Diseases
Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research.
Neuroinflammatory Diseases
The expression levels of prolyl oligopeptidase responds not only to neuroinflammation but also to systemic inflammation upon liver failure in rat models and cirrhotic patients.
Non-alcoholic Fatty Liver Disease
Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity.
Obesity
Adipose tissue contribution to plasma fibroblast growth factor 21 and fibroblast activation protein in obesity.
Obesity
Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity.
Obesity, Morbid
Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity.
Osteoporosis
Activity of dipeptidyl peptidase IV and post-proline cleaving enzyme in sera from osteoporotic patients.
Osteosarcoma
Fibroblast activation protein in osteosarcoma cells promotes angiogenesis via AKT and ERK signaling pathways.
Osteosarcoma
Overexpression of fibroblast activation protein and its clinical implications in patients with osteosarcoma.
Osteosarcoma
The role of fibroblast activation protein in progression and development of osteosarcoma cells.
Ovarian Neoplasms
Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21.
Ovarian Neoplasms
High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer.
Pancreatic Neoplasms
Fibroblast activation protein ?-positive pancreatic stellate cells promote the migration and invasion of pancreatic cancer by CXCL1-mediated Akt phosphorylation.
Pancreatic Neoplasms
Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model.
Pancreatic Neoplasms
The prolyl peptidases PRCP/PREP regulate IRS-1 stability critical for rapamycin-induced feedback activation of PI3K and AKT.
Pancreatic Neoplasms
Theranostics targeting fibroblast activation protein in the tumor stroma: 64Cu and 225Ac labelled FAPI-04 in pancreatic cancer xenograft mouse models.
Paraproteinemias
Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma.
Parkinson Disease
A prolyl oligopeptidase inhibitor, KYP-2047, reduces ?-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.
Parkinson Disease
Comparison of proline endopeptidase activity in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease.
Parkinson Disease
Computer-Aided Drug Discovery Identifies Alkaloid Inhibitors of Parkinson's Disease Associated Protein, Prolyl Oligopeptidase.
Parkinson Disease
Effects of the prolyl endopeptidase inhibitor S 17092 on cognitive deficits in chronic low dose MPTP-treated monkeys.
Parkinson Disease
Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the ?-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing ?-Synuclein Oligomeric Species in Mouse Brain.
Parkinson Disease
Investigation of novel chemical scaffolds targeting prolyl oligopeptidase for neurological therapeutics.
Parkinson Disease
Prolyl Endopeptidase-Like Facilitates the ?-Synuclein Aggregation Seeding, and This Effect Is Reverted by Serine Peptidase Inhibitor PMSF.
Parkinson Disease
Prolyl oligopeptidase and dipeptidyl peptidase II/dipeptidyl peptidase IV ratio in the cerebrospinal fluid in Parkinson's disease: historical overview and future prospects.
Parkinson Disease
Prolyl Oligopeptidase Enhances ?-Synuclein Dimerization via Direct Protein-Protein Interaction.
Parkinson Disease
Removal of prolyl oligopeptidase reduces alpha-synuclein toxicity in cells and in vivo.
Parkinson Disease
The effect of prolyl oligopeptidase inhibitors on alpha-synuclein aggregation and autophagy cannot be predicted by their inhibitory efficacy.
Periodontitis
Activity of dipeptidyl peptidase II and dipeptidyl peptidase IV in human gingiva with chronic marginal periodontitis.
Phyllodes Tumor
miR-21 induces myofibroblast differentiation and promotes the malignant progression of breast phyllodes tumors.
Prostatic Neoplasms
Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells.
Pulmonary Fibrosis
Effects of the fibroblast activation protein inhibitor, PT100, in a murine model of pulmonary fibrosis.
Sarcoma
Fibroblast activation protein increases metastatic potential of fibrosarcoma line HT1080 through upregulation of integrin-mediated signaling pathways.
Sarcoma
Ga-68-FAPI as diagnostic tool in sarcoma: Data from the FAPI-PET prospective observational trial.
Sarcoma
Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT.
Sarcoma
Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin.
Scleroderma, Systemic
Circulating fibroblast activation protein and dipeptidyl peptidase 4 in rheumatoid arthritis and systemic sclerosis.
Seizures
Pentylenetetrazol-induced seizures affect the levels of prolyl oligopeptidase, thimet oligopeptidase and glial proteins in rat brain regions, and attenuation by MK-801 pretreatment.
Squamous Cell Carcinoma of Head and Neck
Fibroblast Activation Protein (FAP) Overexpression Induces Epithelial-Mesenchymal Transition (EMT) in Oral Squamous Cell Carcinoma by Down-Regulating Dipeptidyl Peptidase 9 (DPP9).
Stomach Neoplasms
Activated gastric cancer-associated fibroblasts contribute to the malignant phenotype and 5-FU resistance via paracrine action in gastric cancer.
Stomach Neoplasms
Effects of the fibroblast activation protein on the invasion and migration of gastric cancer.
Stomach Neoplasms
Prolyl oligopeptidase inhibition-induced growth arrest of human gastric cancer cells.
Stomach Neoplasms
Roles of Fibroblast Activation Protein and Hepatocyte Growth Factor Expressions in Angiogenesis and Metastasis of Gastric Cancer.
Stomach Neoplasms
Roles of fibroblasts from the interface zone in invasion, migration, proliferation and apoptosis of gastric adenocarcinoma.
Synucleinopathies
P2-substituted N-acylprolylpyrrolidine inhibitors of prolyl oligopeptidase: biochemical evaluation, binding mode determination, and assessment in a cellular model of synucleinopathy.
Synucleinopathies
Prolyl Oligopeptidase Enhances ?-Synuclein Dimerization via Direct Protein-Protein Interaction.
Thrombosis
Plasma levels of soluble fibroblast activation protein in arterial thrombosis: determinants and cleavage of its substrate alpha-2-antiplasmin.
Trypanosomiasis
The Trypanosoma cruzi virulence factor oligopeptidase B (OPBTc) assembles into an active and stable dimer.
Tuberculosis
Mycobacterium tuberculosis puromycin hydrolase displays a prolyl oligopeptidase fold and an acyl aminopeptidase activity.
Tuberculosis
Significant accumulations of cathepsin B and prolylendopeptidase in inflammatory focus of delayed-type hypersensitivity induced by Mycobacterium tuberculosis in mice.
Ureteral Obstruction
Thymosin ?4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis.
Urinary Bladder Neoplasms
Stromal marker fibroblast activation protein drives outcome in T1 non-muscle invasive bladder cancer.
Vaccinia
Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy.
Venous Insufficiency
The Inhibition of Prolyl Oligopeptidase as New Target to Counteract Chronic Venous Insufficiency: Findings in a Mouse Model.
Virus Diseases
Intrahepatic expression of collagen and fibroblast activation protein (FAP) in hepatitis C virus infection.
Virus Diseases
Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
wild type enzyme and mutant S477C, hanging drop vapor diffusion method, using 30% (w/v) PEG 8K and 100 mM Tris-HCl (pH 9.0)
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Ellis-Guardiola, K.; Rui, H.; Beckner, R.L.; Srivastava, P.; Sukumar, N.; Roux, B.; Lewis, J.C.
Crystal structure and conformational dynamics of Pyrococcus furiosus prolyl oligopeptidase
Biochemistry
58
1616-1626
2019
Pyrococcus furiosus (Q51714), Pyrococcus furiosus
brenda
EXTERNAL LINKS (specific for EC-Number 3.4.21.26)
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
